Literature DB >> 15018712

Evaluation of combination DNA/replication-competent Ad-SIV recombinant immunization regimens in rhesus macaques.

Nina Malkevitch1, Daniela Rohne, Joel Pinczewski, Kristine Aldrich, V S Kalyanaraman, Norman L Letvin, Marjorie Robert-Guroff.   

Abstract

Combination vaccine regimens in which priming with recombinant DNA is followed by boosting with recombinant viral vectors have been shown in previous studies to effectively enhance cellular immunity. However, no information exists concerning possible synergy of the cellular immune response when DNA immunization is followed by administration of a recombinant vector able to replicate. As our approach makes use of replication-competent Ad HIV and SIV recombinants, we performed a pilot experiment in six rhesus macaques in which we compared immunogenicity resulting from priming with one or two DNA recombinants encoding the SIVsmH4 env and rev genes with that elicited by a single replication-competent Ad5hr-SIV env/rev priming immunization. All macaques were subsequently administered an Ad5hr-SIV env/rev booster immunization followed by two immunizations with SIV gp120 protein. The choice of the env gene as target immunogen allowed comparison of induced cellular immune responses as well as binding and neutralizing antibodies elicited in serum and mucosal secretions. We report here that all immunized monkeys developed strong cellular immunity to the SIV envelope as shown by secretion of interferon-gamma, lysis of envelope-expressing target cells, and/or proliferation in response to gp120 or inactivated SIV. Similarly, all macaques developed anti-gp120 binding antibodies and neutralizing antibodies in serum and IgG and IgA binding antibodies in mucosal secretions. We did not observe consistently enhanced immune responses in any immunization group. We conclude that two sequential immunizations with the same replication-competent Ad5hr-SIV recombinant is as effective as priming with one or two recombinant DNA vaccines followed by a single Ad5hrSIV recombinant immunization.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15018712     DOI: 10.1089/088922204773004969

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  5 in total

1.  Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization.

Authors:  Wing-pui Kong; Ling Xu; Konrad Stadler; Jeffrey B Ulmer; Sergio Abrignani; Rino Rappuoli; Gary J Nabel
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

2.  Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques.

Authors:  Lauren A Hirao; Ling Wu; Amir S Khan; David A Hokey; Jian Yan; Anlan Dai; Michael R Betts; Ruxandra Draghia-Akli; David B Weiner
Journal:  Vaccine       Date:  2008-03-11       Impact factor: 3.641

3.  Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques.

Authors:  Izabela Bialuk; Stephen Whitney; Vibeke Andresen; Ruth H Florese; Janos Nacsa; Valentina Cecchinato; Valerio W Valeri; Jean-Michel Heraud; Shari Gordon; Robyn Washington Parks; David C Montefiori; David Venzon; Thorsten Demberg; Marjorie Robert- Guroff; Gary Landucci; Donald N Forthal; Genoveffa Franchini
Journal:  Vaccine       Date:  2011-10-27       Impact factor: 3.641

4.  Sequential priming with simian immunodeficiency virus (SIV) DNA vaccines, with or without encoded cytokines, and a replicating adenovirus-SIV recombinant followed by protein boosting does not control a pathogenic SIVmac251 mucosal challenge.

Authors:  Thorsten Demberg; Jean D Boyer; Nina Malkevich; L Jean Patterson; David Venzon; Ebonita L Summers; Irene Kalisz; V S Kalyanaraman; Eun Mi Lee; David B Weiner; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2008-08-27       Impact factor: 5.103

Review 5.  Current progress in the development of a prophylactic vaccine for HIV-1.

Authors:  Lena J Gamble; Qiana L Matthews
Journal:  Drug Des Devel Ther       Date:  2010-12-22       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.